Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital, posted the following on LinkedIn:
“The KEYNOTE-522 trial shows that adding pembrolizumab to the standard neoadjuvant chemotherapy significantly boosts outcomes for early-stage triple-negative breast cancer patients. The study previously found higher pathological complete response rates, along with better event-free survival.
A recent update showed a significant improvement in overall survival rate, compared to just chemotherapy, cutting the risk of death by more than 34%.
This is great news for patients with high-risk early-stage triple-negative breast cancer, confirming immunotherapy is a major advance in breast cancer therapy.”
Source: Francisco J. Esteva/LinkedIn